Effects of postopertive anti-viral therapy using adefovir dipivoxil on recurrence of hepatocellular carcinoma with HBV infection
10.3760/cma.j.issn.1673-4203.2009.11.010
- VernacularTitle:阿德福韦酯对HBV感染肝细胞癌患者根治术后复发的影响
- Author:
Funan QIU
;
Yifeng TIAN
;
Zhide LAI
;
Yaodong WANG
- Publication Type:Journal Article
- Keywords:
hepatic tumor;
DNA virus;
hepatitis B virus;
neoplasm recurrence
- From:
International Journal of Surgery
2009;36(11):747-750
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of postoperative anti-viral therapy using adefovir dipivoxil in recurrence of hepatocellular carcinoma HCC with HBV infection. Methods Sixty HCC patients with HBV infection were randomized into two groups:Group A (n=23) received hepatectomy only, and Group B (n=37) received hepatectomy and postoperative therapy using adefovir dipivoxil. The changes in liver func-tion, the suppression of HBV-DNA, HBeAg seroconversion rate, tumor recurrence rate and median survival in the two groups were observed and compared. Results In Group B, serum albumin, total bilirubin, AST and ALT were significantly improved compared with Group A (P < 0.05). Furthermore, the rate of 6-month and 1-year HBV-DNA suppression, the rate of 6-month and 1-year HBeAg seroconversion were significantly improved compared with Group A (P < 0.05). In Group A and Group B the tumor recurrence rate was 82. 6% (19/23) vs 78.4% (29/37) (P > 0.05), the recurrence time was 7.3 vs9.6 months (P > 0.05) and the median survival time was 17.4 vs 24.9 months (P < 0.01). Conclusion The results suggest that an-ti-viral therapy using adefovir dipivoxil postoperatively may improve the remnant liver function, suppress the HBV reaction, prolong the survival for patients with HCC with HBV infection.
